Delving into the Latest Updates on Procaterol Hydrochloride Hydrate with Synapse

主要目的比较空腹和餐后给药条件下，黑龙江龙德药业有限公司提供的盐酸丙卡特罗颗粒（1g:50μg）与大塚製薬株式会社持证的盐酸丙卡特罗干糖浆（商品名：Meptin®，规格：0.005%）在健康成年人群中吸收程度和速度的差异，评价其生物等效性。次要目的评价空腹和餐后给药条件下，黑龙江龙德药业有限公司提供的盐酸丙卡特罗颗粒（1g:50μg）与大塚製薬株式会社持证的盐酸丙卡特罗干糖浆（商品名：Meptin®，规格：0.005%）在健康成年人群中的安全性。

[Translation]

main purpose Comparing the conditions of fasting and postprandial administration, Procaterol Hydrochloride Granules (1g:50μg) provided by Heilongjiang Longde Pharmaceutical Co., Ltd. and Procaterol Hydrochloride Dry Syrup (Trade Name: Meptin®) certified by Otsuka Manufacturing Co., Ltd. , Specification: 0.005%) in healthy adults, the degree and rate of absorption are different, and its bioequivalence is evaluated. secondary purpose To evaluate the conditions of fasting and postprandial administration, Procaterol Hydrochloride Granules (1g:50μg) provided by Heilongjiang Longde Pharmaceutical Co., Ltd. and Procaterol Hydrochloride Dry Syrup (trade name: Meptin®) certified by Otsuka Manufacturing Co., Ltd. , specification: 0.005%) safety in healthy adults.

Start Date08 Nov 2024

Sponsor / Collaborator

Heilongjiang Longde Pharmaceutical Co., Ltd.

CTR20243542 / Active, not recruitingNot Applicable

盐酸丙卡特罗干糖浆在中国健康人群中单次给药的人体生物等效性临床试验

[Translation] A human bioequivalence clinical trial of single-dose Procaterol hydrochloride dry syrup in healthy Chinese people

主要目的：以持证商为大塚製薬株式会社的盐酸丙卡特罗干糖浆（商品名：Meptin，规格：0.005%（g/g））为参比制剂，以重庆万霖生物医药科技有限公司研发的盐酸丙卡特罗干糖浆（规格：10g：0.5mg）为受试制剂，评价两种制剂在中国健康受试者中空腹和餐后状态下的生物等效性。次要目的：观察受试制剂和参比制剂在中国健康受试者中的安全性。

[Translation]

Main purpose: Use Procaterol Hydrochloride Dry Syrup (trade name: Meptin, Specification: 0.005% (g/g)) from Otsuka Seiki Co., Ltd. as the reference preparation, and Chongqing Wanlin Biomedical Technology Co., Ltd. The developed procaterol hydrochloride dry syrup (specification: 10g: 0.5mg) was the test preparation to evaluate the bioequivalence of the two preparations in Chinese healthy subjects under fasting and postprandial conditions. Secondary purpose: To observe the safety of the test preparation and reference preparation in Chinese healthy subjects.

Start Date14 Oct 2024

Sponsor / Collaborator

Chongqing Wanlin Biomedical Technology Co., Ltd.

CTR20242018 / CompletedNot Applicable

随机、开放、单剂量、两制剂、自身交叉对照设计，评价中国健康受试者在空腹及餐后状态下单次口服盐酸丙卡特罗颗粒的生物等效性正式试验

[Translation] A randomized, open-label, single-dose, two-drug, self-crossover controlled study to evaluate the bioequivalence of a single oral dose of Procaterol Hydrochloride Granules in Chinese healthy subjects in the fasting and fed state

主要目的：以浙江百代医药科技有限公司提供的盐酸丙卡特罗颗粒为受试制剂，按生物等效性试验的有关规定，与大塚制药株式会社持证的盐酸丙卡特罗颗粒（商品名：Meptin®，参比制剂）对比在健康人体内的吸收速度及吸收程度，考察两制剂的人体生物等效性。次要目的：观察受试制剂盐酸丙卡特罗颗粒和参比制剂盐酸丙卡特罗颗粒（Meptin®）在健康受试者中的安全性。

[Translation]

Main purpose: Using the procaterol hydrochloride granules provided by Zhejiang EMI Pharmaceutical Technology Co., Ltd. as the test preparation, according to the relevant regulations of bioequivalence testing, it is compared with the certified procaterol hydrochloride granules from Otsuka Pharmaceutical Co., Ltd. (trade name: Meptin ®, reference preparation) was compared with the absorption speed and degree of absorption in healthy humans to examine the human bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation Procaterol Hydrochloride Granules and the reference preparation Procaterol Hydrochloride Granules (Meptin®) in healthy subjects.

Start Date03 Jul 2024

Sponsor / Collaborator

Zhejiang Bio-diamond Pharmaceutical Technology Co., Ltd.

100 Clinical Results associated with Procaterol Hydrochloride Hydrate

Login to view more data

100 Translational Medicine associated with Procaterol Hydrochloride Hydrate

Login to view more data

100 Patents (Medical) associated with Procaterol Hydrochloride Hydrate

Login to view more data

444

Literatures (Medical) associated with Procaterol Hydrochloride Hydrate

01 Apr 2024·Biochemical and Biophysical Research Communications

Inhibition of ezrin phosphorylation by NSC305787 attenuates procaterol-stimulated ciliary beating in airway cilia

Article

Author: Wang, Haoting ; Kawaguchi, Kotoku ; Asano, Shinji ; Yokoyama, Sakura

Ciliary beating in the airway epithelium plays an important role in preventing infection by eliminating small particles and pathogens. Stimulation of β₂ adrenergic receptor (β₂AR) increases [cAMP]_i levels and strongly activates this ciliary beating. β₂AR is localized to the apical membrane of the airways by indirectly binding to ezrin, an actin-binding protein. Ezrin takes active phosphorylated and inactive dephosphorylated states at Thr-567. Previously we showed that procaterol-stimulated ciliary beating was impaired in the ezrin-knockdown mice. In this study, we examined the roles of ezrin and its phosphorylation in regulating ciliary beating by using NSC305787, an ezrin inhibitor, in normal human airway epithelial cells (NHBE). We found that NSC305787 inhibits the phosphorylation of ezrin with an IC₅₀ of 50 μM in NHBE. Treatment with NSC305787 for 4 h or more decreased the expression of β₂AR in the cell membrane and induced vesicle- or dot-like expression of ezrin and β₂AR inside the cell. As a result, inhibition of ezrin phosphorylation by NSC305787 attenuated the effect of procaterol-induced activation of ciliary beating in both frequency and distance indices.

01 Feb 2024·Minerva Pediatrics

Value exploration of treating pediatric pneumonia with ambroxol hydrochloride and procaterol hydrochloride

Article

Author: Liu, Xiaoxiao ; Dong, Yan ; Lv, Wei

01 Jan 2024·OMICS: A Journal of Integrative Biology

Cisplatin and Procaterol Combination in Gastric Cancer? Targeting Checkpoint Kinase 1 for Cancer Drug Discovery and Repurposing by an Integrated Computational and Experimental Approach

Article

Author: George, Mejo ; Dagamajalu, Shobha ; Prasad, Thottethodi Subrahmanya Keshava ; Giridhara Prema, Suchitha ; Raju, Rajesh ; Balaya, Rex Devasahayam Arokia ; Kanekar, Saptami ; Chandrasekaran, Jaikanth

Checkpoint kinase 1 (CHK1), a serine/threonine kinase, plays a crucial role in cell cycle arrest and is a promising therapeutic target for drug development against cancers. CHK1 coordinates cell cycle checkpoints in response to DNA damage, facilitating repair of single-strand breaks, and maintains the genome integrity in response to replication stress. In this study, we employed an integrated computational and experimental approach to drug discovery and repurposing, aiming to identify a potent CHK1 inhibitor among existing drugs. An e-pharmacophore model was developed based on the three-dimensional crystal structure of the CHK1 protein in complex with CCT245737. This model, characterized by seven key molecular features, guided the screening of a library of drugs through molecular docking. The top 10% of scored ligands were further examined, with procaterol emerging as the leading candidate. Procaterol demonstrated interaction patterns with the CHK1 active site similar to CHK1 inhibitor (CCT245737), as shown by molecular dynamics analysis. Subsequent in vitro assays, including cell proliferation, colony formation, and cell cycle analysis, were conducted on gastric adenocarcinoma cells treated with procaterol, both as a monotherapy and in combination with cisplatin. Procaterol, in synergy with cisplatin, significantly inhibited cell growth, suggesting a potentiated therapeutic effect. Thus, we propose the combined application of cisplatin and procaterol as a novel potential therapeutic strategy against human gastric cancer. The findings also highlight the relevance of CHK1 kinase as a drug target for enhancing the sensitivity of cytotoxic agents in cancer.

100 Deals associated with Procaterol Hydrochloride Hydrate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	Procaterol Hydrochloride Hydrate	R03AC16 R03CC08	DB01366

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Pulmonary Disease, Chronic Obstructive	CN	Zhejiang Otsuka Pharmaceutical Co. Ltd.	01 Jan 1993
Asthma	JP	Otsuka Pharmaceutical Co., Ltd.	25 Oct 1980

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 1	TW	Taiwan Otsuka Pharmaceutical Co., Ltd.	01 Mar 2009
Acute asthma	Phase 1	ID	PT Otsuka Indonesia	01 Jun 2007

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ERS2013	Not Applicable	Pulmonary Disease, Chronic Obstructive	-	SABA (20 Âµg of inhaled procaterol)	cipcwqobwh(tiqcapmfjo) = fcmlckxqiy bkoufgwzbr (pnlloxxeoz ) View more	Positive	01 Sep 2013
				Placebo	cipcwqobwh(tiqcapmfjo) = scqfkcmwwe bkoufgwzbr (pnlloxxeoz ) View more